80 related articles for article (PubMed ID: 22397022)
1. Gene fusion implicated in lung cancer occurrence.
Hadjivasiliou A
Expert Rev Proteomics; 2012; 9(1):6. PubMed ID: 22397022
[No Abstract] [Full Text] [Related]
2. [The progress of KIF5B-RET fusion gene in non-small cell lung cancer].
Jin LL; Kong H; Xie WP
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):524-6. PubMed ID: 24262090
[No Abstract] [Full Text] [Related]
3. RET fusion genes in non-small-cell lung cancer.
Chao BH; Briesewitz R; Villalona-Calero MA
J Clin Oncol; 2012 Dec; 30(35):4439-41. PubMed ID: 23150705
[No Abstract] [Full Text] [Related]
4. Chipping away at the lung cancer genome.
Pao W; Hutchinson KE
Nat Med; 2012 Mar; 18(3):349-51. PubMed ID: 22395697
[No Abstract] [Full Text] [Related]
5. FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
Velcheti V; Thawani R; Khunger M; Mukhopadhyay S; Chute DJ; Schrock AB; Ali SM
J Thorac Oncol; 2017 Feb; 12(2):e15-e16. PubMed ID: 28115111
[No Abstract] [Full Text] [Related]
6. [Personalized medicine in non-small-cell carcinoma].
Iwama E; Takayama K; Baba E; Nakanishi Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):57-66. PubMed ID: 25000657
[No Abstract] [Full Text] [Related]
7. WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
Velcheti V; Madison R; Ali SM; Schrock AB
J Thorac Oncol; 2018 Jul; 13(7):e122-e123. PubMed ID: 29935851
[No Abstract] [Full Text] [Related]
8. A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer.
Wijesinghe P; Bepler G; Bollig-Fischer A
J Thorac Oncol; 2015 Feb; 10(2):381-6. PubMed ID: 25384172
[TBL] [Abstract][Full Text] [Related]
9. A Novel Oncogenic RET Fusion Variant in Non-Small Cell Lung Cancer: RELCH-RET.
Jiang H; Xiao M; Qi C; Cai S; Liu F
J Thorac Oncol; 2020 Feb; 15(2):e27-e28. PubMed ID: 32127187
[No Abstract] [Full Text] [Related]
10. [Significances of RET fusion gene in non-small cell lung cancer].
Liu J; Bi M
Zhongguo Fei Ai Za Zhi; 2013 Nov; 16(11):615-20. PubMed ID: 24229630
[TBL] [Abstract][Full Text] [Related]
11. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
[TBL] [Abstract][Full Text] [Related]
12. Genomic classification of lung cancer: toward a personalized treatment.
Mlika M; Laabidi S; Afrit M; Boussen H; El Mezni F
Tunis Med; 2015 Jun; 93(6):339-44. PubMed ID: 26644092
[TBL] [Abstract][Full Text] [Related]
13. Defining resistance mechanisms to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Tan L; Solomon BJ
Ann Oncol; 2020 Dec; 31(12):1599-1600. PubMed ID: 33045324
[No Abstract] [Full Text] [Related]
14. A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET.
Myrand SP
J Thorac Oncol; 2021 Oct; 16(10):e95. PubMed ID: 34561049
[No Abstract] [Full Text] [Related]
15. Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".
Lin JJ; Solomon BJ
J Thorac Oncol; 2020 Jul; 15(7):e127-e128. PubMed ID: 32593454
[No Abstract] [Full Text] [Related]
16. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma.
Mizukami T; Shiraishi K; Shimada Y; Ogiwara H; Tsuta K; Ichikawa H; Sakamoto H; Kato M; Shibata T; Nakano T; Kohno T
J Thorac Oncol; 2014 May; 9(5):622-30. PubMed ID: 24722152
[TBL] [Abstract][Full Text] [Related]
17. [Expert consensus on clinical practice of RET fusion detection in non-small cell lung cancer in China].
; ;
Zhonghua Bing Li Xue Za Zhi; 2021 Jun; 50(6):583-591. PubMed ID: 34078044
[TBL] [Abstract][Full Text] [Related]
18. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
19. Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
Zhu VW; Madison R; Schrock AB; Ou SI
J Thorac Oncol; 2020 Jul; 15(7):e124-e127. PubMed ID: 32593453
[No Abstract] [Full Text] [Related]
20. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
